



**Cite this article:** Chua SL *et al.* 2016 Reactive oxygen species drive evolution of pro-biofilm variants in pathogens by modulating cyclic-di-GMP levels. *Open Biol.* **6**: 160162. <http://dx.doi.org/10.1098/rsob.160162>

Received: 2 June 2016  
Accepted: 23 October 2016

**Subject Area:**  
microbiology/systems biology

**Keywords:**  
biofilms, c-di-GMP, rough small colony variants, reactive oxygen species, *Pseudomonas aeruginosa*, adaptive evolution

**Authors for correspondence:**  
Song Lin Chua  
e-mail: sl.chua@ntu.edu.sg  
Liang Yang  
e-mail: yangliang@ntu.edu.sg

Electronic supplementary material is available online at <https://dx.doi.org/10.6084/m9.figshare.c.3569427>.

# Reactive oxygen species drive evolution of pro-biofilm variants in pathogens by modulating cyclic-di-GMP levels

Song Lin Chua<sup>1,3</sup>, Yichen Ding<sup>3,4</sup>, Yang Liu<sup>3</sup>, Zhao Cai<sup>3,4</sup>, Jianuan Zhou<sup>3,5</sup>, Sanjay Swarup<sup>3,6,7</sup>, Daniela I. Drautz-Moses<sup>3</sup>, Stephan Christoph Schuster<sup>2,3</sup>, Staffan Kjelleberg<sup>3,8</sup>, Michael Givskov<sup>3,9</sup> and Liang Yang<sup>2,3</sup>

<sup>1</sup>Lee Kong Chian School of Medicine, and <sup>2</sup>School of Biological Sciences, Nanyang Technological University, Singapore 639798

<sup>3</sup>Singapore Centre for Environmental Life Sciences Engineering (SCElse), and <sup>4</sup>Interdisciplinary Graduate School, Nanyang Technological University, Singapore 637551

<sup>5</sup>Integrative Microbiology Research Centre, South China Agricultural University, Guangzhou 510642, People's Republic of China

<sup>6</sup>Department of Biological Sciences, National University of Singapore, Singapore 117543

<sup>7</sup>NUS Environmental Research Institute, National University of Singapore, Singapore

<sup>8</sup>Center for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney 2052, Australia

<sup>9</sup>Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, 2200 København N, Denmark

SLC, 0000-0001-7047-7451

The host immune system offers a hostile environment with antimicrobials and reactive oxygen species (ROS) that are detrimental to bacterial pathogens, forcing them to adapt and evolve for survival. However, the contribution of oxidative stress to pathogen evolution remains elusive. Using an experimental evolution strategy, we show that exposure of the opportunistic pathogen *Pseudomonas aeruginosa* to sub-lethal hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) levels over 120 generations led to the emergence of pro-biofilm rough small colony variants (RSCVs), which could be abrogated by L-glutathione antioxidants. Comparative genomic analysis of the RSCVs revealed that mutations in the *wspF* gene, which encodes for a repressor of WspR diguanylate cyclase (DGC), were responsible for increased intracellular cyclic-di-GMP content and production of Psl exopolysaccharide. Psl provides the first line of defence against ROS and macrophages, ensuring the survival fitness of RSCVs over wild-type *P. aeruginosa*. Our study demonstrated that ROS is an essential driving force for the selection of pro-biofilm forming pathogenic variants. Understanding the fundamental mechanism of these genotypic and phenotypic adaptations will improve treatment strategies for combating chronic infections.

## 1. Background

Bacterial pathogens can colonize human hosts for years and cause persistent/chronic infections [1,2]. These infections predominantly result from biofilm formation, whereby secreted extracellular-polymeric substances (EPS) such as adhesive proteins, biosurfactants, extracellular DNA and exopolysaccharides act as physical barriers to protect bacterial cells from the host immune clearance and antimicrobial treatments [3–5].

The transition between free-living planktonic and sessile biofilm lifestyles of most bacterial species is mediated by bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP), a global intracellular secondary messenger [6,7]. Increase in intracellular c-di-GMP content is caused by the activity of

diguanylate cyclases (DGCs) [8,9], resulting in biofilm formation, whereas phosphodiesterases (PDEs) degrade c-di-GMP [10,11] and cause biofilm dispersal to the planktonic phase [12,13]. C-di-GMP signalling is involved not only in motility, surface attachment and production of EPS [14–16], but also in the sensing of chemicals and surfaces [8]. C-di-GMP signalling also regulates virulence and stress responses in pathogens [17,18].

*Pseudomonas aeruginosa* is the leading cause of chronic lung infection and morbidity of patients with cystic fibrosis (CF) [19,20]. It is able to survive and form biofilms despite the presence of a functional host immune system, antibiotic treatments and competing pathogens, such as *Staphylococcus aureus* in the CF lung environment [21–24]. Investigations of adaptive evolution of *P. aeruginosa* in CF lung infections have provided valuable information for our current understanding of chronic infections. *P. aeruginosa* can colonize the CF lungs for decades and usually gives rise to pro-biofilm sub-populations after adaptive evolution [25,26]. The occurrence of rough small colony variants (RSCVs) and mucoid strains is often reported from chronic CF infections, implying these variants have better fitness than their ancestors [27,28].

Although the characteristics of RSCVs have been studied [29,30], the stimuli and mechanisms leading to the evolution of such adapted sub-populations are unclear. Given the CF environment consists of oxidative stress, high antibiotic concentrations, high pro-inflammatory cytokine levels and poor nutrient conditions [31–35], it is highly likely that each of the CF-derived environmental factors can drive the adaptive evolution of pathogens differently.

Experimental evolution assays have been used in previous studies to investigate bacterial adaptation to various conditions such as antibiotic treatments and carbon sources [18,36]. Here, we employed the adaptive experimental evolution assay to evolve *P. aeruginosa* against an important host-derived antimicrobial, reactive oxygen species (ROS), resulting in the occurrence of RSCVs with a strong capability for biofilm formation and ROS stress resistance.

The RSCVs isolated from H<sub>2</sub>O<sub>2</sub> treated cultures showed increased intracellular c-di-GMP content. Next-generation sequencing (NGS) analysis revealed that *wspF* mutation was associated with these isolated RSCVs. The *wspF* is part of the chemosensory-like system Wsp (wrinkly spreader phenotype) [8], whose product acts as a repressor against WspR (DGC), thus its mutagenesis leads to the de-repression of WspR. The increased production of exopolysaccharides (especially Psl) as the result of *wspF* mutation conferred resistance of RSCVs to H<sub>2</sub>O<sub>2</sub> treatment. Hence, this work strongly suggests that exposure to ROS imposes a strong selective pressure on *P. aeruginosa* during chronic colonization and accounts for the occurrence of RSCVs in clinical isolates obtained from CF patients.

## 2. Material and methods

### 2.1. Bacterial strains, plasmids, media and growth conditions

*Escherichia coli* DH5 $\alpha$  strain was used for standard DNA manipulations. Luria-Bertani (LB) medium was used to cultivate *E. coli* strains. Batch cultivation of *P. aeruginosa* strains was carried out at 37°C in ABTG (ABT minimal medium

supplemented with 5 g l<sup>-1</sup> glucose) or ABTGC (ABT minimal medium supplemented with 2 g l<sup>-1</sup> glucose and 2 g l<sup>-1</sup> cas-amino acids). For plasmid maintenance in *E. coli*, the medium was supplemented with 100  $\mu$ g ml<sup>-1</sup> ampicillin (Ap), 15  $\mu$ g ml<sup>-1</sup> gentamicin (Gm) and 15  $\mu$ g ml<sup>-1</sup> tetracycline (Tc). When appropriate, the marker selection in *P. aeruginosa*, 30  $\mu$ g ml<sup>-1</sup> Gm, 50  $\mu$ g ml<sup>-1</sup> Tc or 200  $\mu$ g ml<sup>-1</sup> carbenicillin (Cb), was used. The bacterial strains and plasmids are listed in the electronic supplementary material, table S1.

### 2.2. Imaging colony morphology of *Pseudomonas aeruginosa*

Cultures were streaked on LB agar together with 40  $\mu$ g ml<sup>-1</sup> Congo Red and 15  $\mu$ g ml<sup>-1</sup> Coomassie Brilliant Blue R at 37°C for 48 h as previously described [37]. Colony images were captured by the stereomicroscope (Zeiss Discovery V8, Germany) and processed using IMARIS software (Bitplane AG, Zurich, Switzerland).

### 2.3. Evolution assay of *Pseudomonas aeruginosa* PAO1 in H<sub>2</sub>O<sub>2</sub> and GSH

Cultures were cultivated overnight from ancestral PAO1 at 37°C, 200 rpm in LB with three biological replicates. Each biological replicate with initially identical populations was then divided into three technical replicates, each grown in ABTGC only or ABTGC with 2 mM H<sub>2</sub>O<sub>2</sub> + 5, 2.5, 1, 0.25, 0.125 or 0 mM GSH. One per cent of each replicate population was transferred to a new tube of fresh ABTGC with and without 2 mM H<sub>2</sub>O<sub>2</sub> + GSH at 37°C, 200 rpm for 12 h, allowing each population to experience an estimated 6.67 generations every passage. This was then repeated for 15 days, so that there were an estimated 120 generations of cells grown in 2 mM H<sub>2</sub>O<sub>2</sub>.

The populations were then cryopreserved with 50% glycerol (cryoprotectant) for revival at a later time. To observe the emergence of unique phenotypes arising from treatment with 2 mM H<sub>2</sub>O<sub>2</sub>, the populations were grown on LB agar plates at 37°C overnight. Ten RSCV isolates were identified from the different replicates and frozen with 50% glycerol.

### 2.4. H<sub>2</sub>O<sub>2</sub> resistance assay

The *P. aeruginosa* cultures were grown overnight and prepared by adjusting the optical density to OD<sub>600</sub> = 0.3 in ABTGC with and without 4 mM H<sub>2</sub>O<sub>2</sub>. The cultures were grown at 37°C, 200 rpm for 4 h. The cell culture was serially diluted and plated on LB agar plates. The culture plates were incubated in 37°C for 16 h. The numbers of colonies were counted for tabulation of log<sub>10</sub> CFU ml<sup>-1</sup>. The log<sub>10</sub> CFU ml<sup>-1</sup> is calculated by log<sub>10</sub>(average number of colonies  $\times$  dilution factor  $\times$  volume used to spread on LB agar plate). Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean  $\pm$  s.d.

### 2.5. Competitive mixed-treatment assay of rough small colony variant isolates and PAO1

The evolved RSCVs and PAO1 cultures were prepared by adjusting the optical density to OD<sub>600</sub> = 0.5 in ABTGC.

Each RSCV was mixed at equal volumes (1:1 ratio) with PAO1 in ABTGC with and without 4 mM H<sub>2</sub>O<sub>2</sub> (1× MIC). The cultures were grown at 37°C, 200 rpm. Twenty microlitre samples were collected after a 4 h incubation. They were diluted serially in 0.9% NaCl and 100 µl of cell culture was cultivated on LB agar plates for 16 h at 37°C. The RSCVs and PAO1 were differentiated by the morphology of the colonies. The number of colonies was counted for tabulation of CFU ml<sup>-1</sup>. The competition ratio was then calculated by CFU ml<sup>-1</sup> of RSCV/CFU ml<sup>-1</sup> of PAO1. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean ± s.d.

## 2.6. DNA sequencing of rough small colony variants isolates

Individual colonies of the ancestral PAO1, two random PAO1 isolates evolved in ABTGC only and 10 RSCV isolates were first streaked on the LB agar plates and incubated at 37°C for 16 h. Single colonies were picked by a 1 µl inoculation loop and grown in LB at 37°C, 200 rpm for 16 h. Genomic DNA of the *P. aeruginosa* strains was purified using QIAamp DNA Mini Kit (Qiagen, Venlo, The Netherlands). The quality control tests included NanoDrop (Thermo Fisher Scientific) and Qubit (Thermo Fisher Scientific) to ensure the concentration and quality of DNA, and DNA electrophoresis (1% agar) to determine DNA integrity.

The genomic DNA was then sequenced on an Illumina (San Diego, CA, USA) MiSeq V3 platform, generating 300 bp long paired-end reads using the method described in Chua *et al.* [38]. The average insert sizes were 490–544 bp, and average genomic coverage depths were 40–186 fold. Nucleotide differences were generated from the CLC GENOMICS WORKBENCH 8.0 (CLC bio, Aarhus, Denmark). Briefly, adapters and low quality reads were trimmed. Paired-end reads in FASTQ format for RSCV and control genomes were mapped against the *P. aeruginosa* PAO1 genome (NC\_002516). Both the mappings of RSCV and control strains were compared with their ancestor PAO1, and variants were detected using the quality based variant detection method with the required frequency of 35%.

## 2.7. Measurement of mutation rates

PAO1 was grown in ABTGC with or without 2 mM H<sub>2</sub>O<sub>2</sub> until stationary phase, and plated on LB agar plates with and without 0.78 µg ml<sup>-1</sup> ciprofloxacin, using the method described in Mandsberg *et al.* [39]. The mutated colonies cultured on LB agar with ciprofloxacin were enumerated to account for point mutations on the *gyr* gene that can easily develop in *P. aeruginosa* exposed to ciprofloxacin [40]. The mutation rate was then calculated by dividing the number of mutations by the final CFU of cells grown on LB agar plates without ciprofloxacin. Three independent experiments were performed in triplicate, the Student's *t*-test was used to determine statistical significance and the results were shown as the mean ± s.d.

## 2.8. The p<sub>cdrA</sub>-gfp reporter assay

The cultures of PAO1 with p<sub>cdrA</sub>-gfp reporter fusion were grown in ABTGC with or without H<sub>2</sub>O<sub>2</sub>. In total, 200 µl of

cell culture was then transferred into each well of a 96-well plate (triplicates). The OD<sub>600</sub> and GFP fluorescence (excitation 485 nm/emission 535 nm) were measured using the Tecan Infinite 200 microplate reader (Tecan, Austria). The relative fluorescence intensity count was calculated by dividing GFP values by OD<sub>600</sub> values. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean ± s.d.

## 2.9. Quantification of pyoverdine

The cultures were grown in ABTGC with or without H<sub>2</sub>O<sub>2</sub>. In total, 200 µl of cell culture was then transferred into each well of a 96-well plate (triplicates). As previously described [13], the OD<sub>600</sub> and pyoverdine fluorescence (excitation 400 nm/emission 460 nm) were measured using the Tecan microplate reader, and the relative fluorescence intensity count calculated by dividing pyoverdine fluorescence values by OD<sub>600</sub> values. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean ± s.d.

## 2.10. C-di-GMP quantification by liquid chromatography–mass spectrometry

Fifteen millilitres of PAO1 cell culture treated with H<sub>2</sub>O<sub>2</sub>, RSCVs, *Burkholderia cenocepacia* strains and *Klebsiella pneumoniae* strains were harvested and washed twice with 1 mM ammonium acetate. An aliquot of cells was used for protein quantification. The remaining cells were lysed in 1 ml acetonitrile/methanol/ddH<sub>2</sub>O (v/v ratio 40:40:20) using a probe tip ultrasonicator (amplitude 30%; 5 s on, 5 s off) for 1 min on an ice slurry. The cell debris was removed by centrifuging at 13 000g, 4°C for 3 min, rinsing twice. The supernatant containing the nucleotides was lyophilized with the vacuum concentrator. The lyophilized nucleotides were resuspended in 100 µl 1 mM ammonium acetate. The c-di-GMP standard was also used as a reference to identify the c-di-GMP peak and the concentration of c-di-GMP in the samples.

For the detection and quantification of c-di-GMP, a Thermo Accela 1250 series LC system fitted with EQUANMax autosampler and a Thermo Velos Pro Orbitrap mass spectrometer (Thermo Fisher Scientific) were used. Chromatographic separation was achieved using a Nucleodur C18 Pyramid (2 mm × 50 mm, 3 µm) column (Macherey-Nagel GmbH, Düren, Germany) at 40°C, with a solvent flow rate of 0.3 ml min<sup>-1</sup> and an injection volume of 10 µl. Buffer A was 10 mM ammonium acetate buffer, containing 0.1% acetic acid, and buffer B was acetonitrile, containing 0.1% acetic acid. Solvent gradient conditions were as follows: 0% B from 0 to 3 min; 10% B at 3 min; 90% from 4th to 5th min; 0% B at 5.5th min and equilibrated for 4.5 min. Total run time was 10 min.

Detection was carried out in positive ion electrospray ionization (ESI+) mode. The heater and capillary temperatures were 300°C. Sheath, auxiliary and sweeper gas flows were 40, 15 and 1 arb. units, respectively. Source voltage was 3.5 kV. For quantitation, scan type in selected ion monitoring mode was used at high-resolution (60 000), with an AGC target of 1 × 10<sup>6</sup>. Quantification was achieved via an MS/MS experiment using collision induced dissociation (CID)

with normalized collision energy 20% (of maximum), with isolation width of 1 Da and activation time of 30 ms.

To quantify protein concentration, a small aliquot of cell culture was lysed in 100  $\mu$ l 5 M sodium hydroxide at 95°C for 5 min. The protein concentration was then measured using a Qubit® 2.0 fluorometer (Invitrogen, Thermo Fisher Scientific, CA). The final concentration of c-di-GMP was then normalized with protein quantity. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used as to determine statistical significance and results were shown as the mean  $\pm$  s.d.

### 2.11. Psl staining by fluorescent concanavalin-A

Planktonic MiniTn7-*gfp*-tagged cells were grown in ABTGC + 0, 0.5, 1 and 2 mM H<sub>2</sub>O<sub>2</sub> at 37°C, 200 rpm for 4 h. Additionally, PAO1, mutants and evolved RSCVs with tagged MiniTn7-*gfp* were grown until stationary phase in ABTGC overnight at 37°C, 200 rpm. Ten microlitres of cell culture were then transferred to the glass slide and stained by 5  $\mu$ M concanavalin-A Alexa Fluor® 647 conjugate (Thermo Fisher Scientific, Cat. No. C21421) [41].

To monitor fluorescence of GFP and Psl stain, the cells were imaged using an LSM780 confocal laser scanning microscope (CLSM; Carl Zeiss, Germany) with 40 $\times$  objective or 63 $\times$  oil objective (for planktonic cells) and the images were processed using IMARIS software (Bitplane AG, Zurich, Switzerland). Three independent experiments were performed in triplicate and representative images were shown.

### 2.12. Arabinose-inducible expression of Psl by PAO1/*p*<sub>BAD</sub>-*psl*

A starting culture of PAO1/*p*<sub>BAD</sub>-*psl* cells containing an *L*-arabinose-inducible promoter for *psl* operon expression was grown in ABTGC with increasing concentrations of *L*-arabinose at 37°C, 200 rpm for 3 h until OD<sub>600</sub> = ~0.3 was established, as described in Irie *et al.* [42]. The cultures were then treated with and without 4 mM H<sub>2</sub>O<sub>2</sub> and continued to be grown at 37°C, 200 rpm for an additional 4 h. The cell culture was serially diluted and plated on LB agar plates. The culture plates were incubated at 37°C for 16 h. The colonies were counted for tabulation of CFU ml<sup>-1</sup>. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used as statistical tests and the results were shown as the mean  $\pm$  s.d.

### 2.13. Biofilm quantification of PAO1/*p*<sub>BAD</sub>-*psl* by crystal violet assay

The PAO1/*p*<sub>BAD</sub>-*psl* biofilms were grown in 1 ml ABTGC with increasing concentrations of *L*-arabinose at 37°C in 24-well plates (Nunc, Denmark). The biofilms were washed three times with 0.9% NaCl and stained with 0.1% crystal violet for 15 min. Excess crystal violet was washed off with 0.9% NaCl. The stained biofilms were dissolved by 100% ethanol and their OD<sub>595</sub> values were quantified using a Tecan Infinite 200 microplate reader (Tecan, Austria). Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean  $\pm$  s.d.

### 2.14. Cellulase treatment of *Pseudomonas aeruginosa* cultures to degrade Psl

The *P. aeruginosa* cultures were grown overnight and prepared by adjusting the optical density to OD<sub>600</sub> = 0.1 in ABTGC with 1 mg ml<sup>-1</sup> cellulase (Sigma-Aldrich, Cat. No. C9748) [42]. The cultures were grown to OD<sub>600</sub> = ~0.3 at 37°C, 200 rpm for 3 h. The cultures were treated with 0 or 4 mM H<sub>2</sub>O<sub>2</sub> and further grown at 37°C, 200 rpm for 4 h. The cell culture was serially diluted and plated on LB agar plates. The culture plates were incubated in 37°C for 16 h. Colonies were counted for tabulation of CFU ml<sup>-1</sup>. Three independent experiments were performed in triplicate. One-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean  $\pm$  s.d.

### 2.15. RAW264.7 macrophages culture


The murine RAW264.7 macrophage cell lines (ATCC No. TIB-71) were cultivated in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS) (Gibco™, Thermo Fisher Scientific). Cell cultures were incubated in 75 cm<sup>2</sup> cell culture flasks at a density of 1.0  $\times$  10<sup>6</sup> cells ml<sup>-1</sup> at 37°C, 5% CO<sub>2</sub> for 72 h.

### 2.16. Macrophage phagocytosis assay

As previously described [12], 5  $\times$  10<sup>5</sup> macrophages were grown in each well of a 24-well culture plate (Nunc, Denmark). Macrophages were infected with bacterial suspension at a multiplicity of infection (MOI) of 100:1. The co-cultures were incubated at 37°C and 5% CO<sub>2</sub> for 2 h. The macrophages were washed three times with phosphate-buffered saline (PBS) to remove extracellular bacteria, and then lysed with ddH<sub>2</sub>O containing 0.5% Triton X-100. The cell lysates were then serially diluted, and 100  $\mu$ l of each dilution was plated on triplicate LB agar plates and incubated overnight at 37°C. The number of colonies was enumerated, and CFU ml<sup>-1</sup> was tabulated. Experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to determine statistical significance and the results were shown as the mean  $\pm$  s.d.

### 2.17. Macrophage cytotoxicity assay

RAW264.7 macrophages (5  $\times$  10<sup>5</sup> ml<sup>-1</sup> in each well) were grown in 24-well culture plates as previously described [12]. Triplicate cultures were infected with bacterial suspension at a MOI of 100:1. Macrophages were incubated for 4 h in 37°C, 5% CO<sub>2</sub>, then 20  $\mu$ M propidium iodide (PI) was used to stain dead cells and assess macrophage cytotoxicity, leaving live cells unstained. Macrophages stained by PI (excitation 535 nm, emission 617 nm) under epifluorescent microscopy (20 $\times$  objective) were counted as dead. Macrophages from five replicate images (on average 100 macrophages per image) of each sample were counted, enabling the ratio of dead cells to live cells to be calculated. Three independent experiments were performed in triplicate, one-way ANOVA and Student's *t*-tests were used to establish statistical significance and the results were shown as the mean  $\pm$  s.d.



**Figure 1.** Evolution assay of *Pseudomonas aeruginosa* in  $H_2O_2$ . (a) Percentage of rough small colony variants (RSCVs) after evolution in the presence of  $H_2O_2$  compared with the control. (b) Resistance of RSCV isolates compared with PAO1 in  $H_2O_2$ . (c) Competitive fitness assay between RSCV isolates and PAO1 grown in  $H_2O_2$ . (d) Antioxidants (glutathione; GSH) reduced the proportion of RSCVs formed with ROS treatment, in a dose-dependent manner. Means  $\pm$  s.d. from triplicate experiments are shown.

### 3. Results

#### 3.1. Emergence of rough small colony variants during adaptive evolution of *Pseudomonas aeruginosa* against ROS

To determine if oxidative stress provokes the adaptive evolution of *P. aeruginosa*, *P. aeruginosa* was cultivated in the presence of a sub-lethal concentration of  $H_2O_2$  (2 mM,  $0.5 \times$  minimal inhibitory concentration (MIC)) for 120 generations. This simulated the presence of ROS produced by polymorphonuclear leucocytes (PMNs) in the CF lung, which generate oxidative stress as a selective pressure on *P. aeruginosa* cells [43]. Although a millimolar range of  $H_2O_2$  is required to kill most bacteria and bacteria internalized in the phagosome are usually exposed to micromolar concentrations, the rates of free radical generation within the phagosome are estimated to be 10 000 times faster, leading to higher concentrations of ROS than have been experimentally tested [44]. Hence, the sufficiently high levels of ROS present can be potentially damaging to bacterial cells.


After 120 generations, colonies with RSCV phenotype were observed on the agar plates inoculated with 2 mM  $H_2O_2$  treatment (electronic supplementary material, figure S1), while no distinctive phenotypes were observed in the control populations without  $H_2O_2$  treatment. The percentage of RSCVs in  $H_2O_2$  exposed *P. aeruginosa* populations reached around 40% (figure 1a), implying that ROS could significantly contribute to the occurrence of RSCVs. We also showed that *P. aeruginosa* was able to evolve within 120 generations, when compared with a shorter 47.5 generation period in the evolution of RSCVs with antibiotics [18]. As *P. aeruginosa* can

**Table 1.** MIC of evolved RSCV isolates to  $H_2O_2$ .

strain/isolate	MIC (mM)
PAO1	4
RSCV 1	32
RSCV 2	64
RSCV 3	64
RSCV 4	64
RSCV 5	64
RSCV 6	32
RSCV 7	64
RSCV 8	64
RSCV 9	8
RSCV 10	64

persist in CF lungs for decades, spanning 200 000 bacterial generations [33,45], there is more than sufficient time for the metabolically active [46] *P. aeruginosa* to adapt in CF lungs.

The resistance of randomly selected RSCV clones to  $H_2O_2$  was then measured. The RSCVs showed up to 16-fold increase in MIC to  $H_2O_2$  (table 1) compared with the ancestral PAO1 strain. The RSCV clones also survived better than PAO1 after treatment with 4 mM  $H_2O_2$  ( $1 \times$  MIC) (figure 1b). Next, we measured the fitness of the selected RSCVs by co-culturing them with ancestral PAO1. In the absence of 2 mM  $H_2O_2$ , the ancestral PAO1 outcompeted the RSCVs (figure 1c), but RSCVs outcompeted PAO1 in the presence of 2 mM  $H_2O_2$  (figure 1d), confirming that the RSCVs were favoured and



**Figure 2.** Adaptation of RSCVs to H<sub>2</sub>O<sub>2</sub> is dependent on induction of c-di-GMP content of isolates. (a) C-di-GMP content of RSCVs quantified by HPLC. (b) The p<sub>cdrA</sub>-gfp expression in RSCVs. (c) Pyoverdine production in RSCVs. (d) Expression of p<sub>lac</sub>-yhjH in RSCVs reduces their resistance to H<sub>2</sub>O<sub>2</sub>. Means ± s.d. from triplicate experiments are shown.

selected for in the presence of oxidative stress. Interestingly, RSCV isolates ‘7’ and ‘8’ showed only slightly higher fitness against the PAO1 ancestral strain, compared with the rest of the RSCV isolates, implying different magnitudes of adaptation within the evolved populations.

We determined if the selection of RSCV by oxidative stress could be neutralized by the addition of L-glutathione, a commonly used antioxidant [47]. As expected, L-glutathione reduced the proportion of RSCVs formed in a dose-dependent manner, compared with that in the absence of antioxidants (figure 1d).


### 3.2. Increased c-di-GMP content confers resistance of rough small colony variants to H<sub>2</sub>O<sub>2</sub>

As c-di-GMP signalling is implicated in RSCV formation [27], we examined the intracellular c-di-GMP content in the selected RSCV isolates. Liquid chromatography–mass spectrometry (LC-MS) quantification of the whole cell extract showed that the RSCV isolates contained higher intracellular c-di-GMP than wild-type *P. aeruginosa* PAO1 (figure 2a). This was in accordance with their higher expression levels of the c-di-GMP reporter fusion p<sub>cdrA</sub>-gfp [48,49] (figure 2b) and higher pyoverdine production [50,51] (figure 2c), compared with that of ancestral PAO1. To confirm that the increased H<sub>2</sub>O<sub>2</sub> resistance of RSCVs was attributed to enhanced intracellular c-di-GMP content, we transformed a p<sub>lac</sub>-yhjH plasmid [52] into the RSCVs to deplete their intracellular c-di-GMP. As expected, constitutive expression of the YhjH PDE in the RSCVs attenuated their resistance to H<sub>2</sub>O<sub>2</sub> (figure 2d). These results indicate that c-di-GMP signalling plays an important role in the evolutionary development of PAO1 to RSCVs under ROS stress and corroborated previous studies showing that CF RSCV isolates possessed high c-di-GMP levels [27].

### 3.3. Comparative genomic analysis of rough small colony variants reveal parallel evolution traits

To gain insights into the underlying genetic changes contributing to c-di-GMP-linked RSCV phenotype development with prolonged oxidative stress via c-di-GMP signalling, we sequenced the genomes of 10 randomly selected RSCV isolates and 2 control PAO1 colonies using the Illumina MiSeq platform. Two random control PAO1 colonies were picked from cultures grown in a medium without H<sub>2</sub>O<sub>2</sub> for 120 generations. A series of point mutations were evident in the sequences of 10 randomly selected RSCVs and control PAO1 colonies, compared with the ancestor PAO1 sequence (electronic supplementary material, tables S2 and S3). The distribution of the identified mutations across the PAO1 genome is illustrated in figure 3a. The functional annotation of these RSCV-associated mutations is listed in the electronic supplementary material, tables S2 and S3. Several parallel evolution traits were observed from both RSCVs and control PAO1 colonies, including mutations in PA0727 and PA0720 (encoding phage-related genes), PA1458 (encoding a two component sensor), exsC (encoding an anti-anti-activator of the type III secretion system), PA2877 (encoding a probable transcriptional regulator), intergenic region 4 699 910 bp and intergenic region 5 242 141 bp.

As *P. aeruginosa* commonly accumulate mutations even in planktonic cultures and the mutations are common between control and ROS-evolved strains, the above-mentioned mutations are not deemed to be generated by ROS pressure. We also found that the mutations were not attributed to highly mutagenic growth conditions, as there was no significant increase in mutation rates with ROS treatment (electronic supplementary material, figure S2) compared with control medium, with the mutation rates similar to previous reports [38]. Moreover, the cell populations did not develop



**Figure 3.** Genetic sequencing for identification of mutation sites. (a) Number of mutations identified in evolved genotypes. (b) Location of mutations in the *wspF* gene of different RSCVs.

mutations in the *mutS* gene, which is important in mismatch repair and its mutation can lead to the emergence of multiple phenotypic variants [53].

Interestingly, there was one parallel evolution trait, *wspF* gene mutation, which could only be detected in the genomes from the RSCVs and not in the control PAO1 colonies. All RSCV genomes had loss of function mutations in the *wspF* gene at different sites (figure 3b; electronic supplementary material, table S1). The  $\Delta wsfF$  mutation caused the de-repression of the WspR DGC, leading to increased c-di-GMP synthesis and high intracellular c-di-GMP content, resulting in bacterial cell clumping (electronic supplementary material, figure S1) [54]. This indicated that enhanced intracellular c-di-GMP content might play a positive role in *P. aeruginosa*'s adaptation to oxidative stress.

### 3.4. Regulatory roles of *wspF* on ROS-mediated resistance of *Pseudomonas aeruginosa*

To investigate whether intracellular c-di-GMP content is increased under conditions of ROS stress, we measured the intracellular c-di-GMP content and expression of c-di-GMP reporter fusion  $p_{cdrA-gfp}$  with  $H_2O_2$  treatment. Both intracellular c-di-GMP content and  $p_{cdrA-gfp}$  expression levels were increased in PAO1 strain after exposure to 4 mM  $H_2O_2$  for 4 h (figure 4a,b). Given the increase in intracellular c-di-GMP content in adaptation to  $H_2O_2$  stress and the presence of *wspF* mutations in our experimental evolution assay, we hypothesized that the genetic basis of adaptation to ROS was directly linked to the mutation in *wspF*, which resulted in the de-repression of *wspR* DGC [8] and a subsequent increased production of c-di-GMP. Hence, we used an isogenic  $\Delta wsfF$  mutant as previously described [51] to ascertain ROS resistance. We also used 'locked' high and low c-di-GMP content strains of PAO1 by using the  $p_{lac-yedQ}$  and  $p_{lac-yhjH}$  plasmids, respectively. The *yedQ* gene encodes an *E. coli* DGC that synthesizes


c-di-GMP [50,55,56], thus the exogenous addition of the  $p_{lac-yedQ}$  would enable the constitutive production of c-di-GMP within the species, resulting in the highly aggregative nature of the colonies (electronic supplementary material, figure S1). The *yhjH* gene encodes an *E. coli* PDE that degrades c-di-GMP [56,57], so the presence of  $p_{lac-yhjH}$  plasmid would cause the reduction of intracellular c-di-GMP levels.

The  $\Delta wsfF$  and PAO1/ $p_{lac-yedQ}$  mutants were more resistant to 4 mM  $H_2O_2$  ( $1 \times$  MIC) than PAO1, while PAO1/ $p_{lac-yhjH}$  was more sensitive to 4 mM  $H_2O_2$  than PAO1 (figures 4c and 5a). Epistatic mutations of *wspR* gene restored  $p_{cdrA-gfp}$  expression (figure 4d) to that of the wild-type of a few selected RSCV isolates. This also caused the RSCV isolates to lose their resistance to  $H_2O_2$  (figure 4e), confirming that PAO1 could adapt to ROS stress simply via the mutagenesis of *wspF*.

As clinical RSCV isolates with *wspF* mutations were isolated from CF patients [27], we also tested the ROS resistance of clinical RSCV isolates with known *wspF* mutations (CF173-2005 isolate of lineage H and a related isolate CF273-2002) [45]. Such RSCV isolates from the CF lungs possess higher c-di-GMP levels [8]. We showed that they were resistant to 4 mM  $H_2O_2$  and the insertion of the  $p_{lac-yhjH}$  plasmid reduced their resistance to ROS (figure 4f). This confirmed that the clinical RSCV isolates were adapted to the presence of ROS in the human body and cemented the involvement of c-di-GMP regulation in biofilm ROS resistance.


### 3.5. C-di-GMP-dependent exopolysaccharides are required for *Pseudomonas aeruginosa* ROS resistance

To understand how the *wsp* operon mediates ROS resistance, we tested whether exopolysaccharides could interfere with the action of ROS on *P. aeruginosa*, as the *wsp* operon regulates the expression of Pel and Psl exopolysaccharide synthetic



**Figure 4.**  $\Delta wspF$  mutation is important in the induction of c-di-GMP in the presence of ROS. (a) Induction of c-di-GMP in PAO1 by short term (4 h) H<sub>2</sub>O<sub>2</sub> exposure (LC-MS quantification). (b) Induction of *p<sub>airA</sub>-gfp* expression level in PAO1 by short term (4 h) H<sub>2</sub>O<sub>2</sub> exposure. (c) Resistance of PAO1,  $\Delta wspF$ , PAO1/*p<sub>lac</sub>-yjhH* and PAO1/*p<sub>lac</sub>-yjhH* strains to 4 mM H<sub>2</sub>O<sub>2</sub>. (d) *p<sub>airA</sub>-gfp* expression of evolved RSCV isolates with epistatic *wspR* mutations to H<sub>2</sub>O<sub>2</sub>. (e) Resistance of evolved RSCV isolates with epistatic *wspR* mutations to H<sub>2</sub>O<sub>2</sub>. (f) Resistance of PAO1 and clinical RSCV isolates with known *wspR* mutations to H<sub>2</sub>O<sub>2</sub> treatment. Means  $\pm$  s.d. from triplicate experiments are shown;  $p < 0.05$ , one-way ANOVA.






**Figure 5.** C-di-GMP-mediated exopolysaccharides were required for resistance to ROS stress. (a) Resistance of PAO1,  $\Delta wspF\Delta pelA\Delta pslBCD$  and  $\Delta pelA\Delta pslBCD/p_{lac-yedQ}$  to  $H_2O_2$ . (b) Psl was more influential than Pel in conferring ROS resistance. (c) Psl staining showed formation of small aggregates and synthesis of larger amounts of Psl in PAO1 treated with 0.5, 1 and 2 mM  $H_2O_2$  compared with control PAO1 cultures. (d) Psl staining revealed synthesis of larger amounts of Psl in representative RSCVs and strains with high intracellular c-di-GMP content than PAO1. (e) Addition of L-arabinose to PAO1/ $p_{BAD-psl}$  increased biofilm formation in a dose-dependent manner. (f) Resistance of PAO1/ $p_{BAD-psl}$  to  $H_2O_2$  increased with increasing L-arabinose concentrations. (g) Cellulase treatment abolished ROS resistance in PAO1/ $p_{BAD-psl}$ . Means  $\pm$  s.d. from triplicate experiments are shown;  $p < 0.05$ , one-way ANOVA.

genes [8]. We showed that both  $\Delta wspF\Delta pelA\Delta pslBCD$  and  $\Delta pelA\Delta pslBCD/p_{lac-yedQ}$  mutants, which could not produce Pel and Psl exopolysaccharides, were highly sensitive to  $H_2O_2$ , even though they contain high intracellular c-di-GMP levels (figure 5a). To identify which of the two exopolysaccharides were more important in conferring ROS resistance, we further showed that the  $\Delta pslBCD/p_{lac-yedQ}$  was more sensitive to ROS than  $\Delta pelA/p_{lac-yedQ}$ , thus providing the first indication that Psl is more important than Pel in conferring ROS resistance (figure 5b). We then stained the Psl using a

fluorescent lectin and observed the formation of small aggregates and enhanced production of Psl in PAO1 with 0.5, 1 and 2 mM  $H_2O_2$  treatment (figure 5c). Moreover, the evolved RSCVs,  $\Delta wspF$  and PAO1/ $p_{lac-yedQ}$  mutants produced higher amounts of Psl than PAO1, as indicated by the fluorescence intensity of the Psl stain (figure 5d).

We further validated the requirement of Psl for ROS resistance by using a PAO1/ $p_{BAD-psl}$  mutant by replacing its native *psl* operon promoter with an L-arabinose-inducible promoter [58]. Upon addition of L-arabinose, there was an increase in



**Figure 6.** Adaptation to H<sub>2</sub>O<sub>2</sub> provides further benefits by conferring protection against macrophages. (a) Quantification of phagocytosed PAO1 and evolved RSCV isolates by macrophages. (b) Quantification of phagocytosed PAO1,  $\Delta wspF$  and PAO1/*p<sub>lac</sub>-yhjH* strains by macrophages. (c) Cytotoxicity assay of macrophages by PAO1,  $\Delta wspF$  and PAO1/*p<sub>lac</sub>-yhjH* strains. (d) Quantification of ROS produced by macrophages in the presence of PAO1,  $\Delta wspF$ , PAO1/*p<sub>lac</sub>-yedQ* and PAO1/*p<sub>lac</sub>-yhjH* strains using ROS detection assay. DCF (e) Quantification of phagocytosed PAO1 and  $\Delta pslBCD$  strains by macrophages. (f) Cytotoxicity assay of macrophages by PAO1 and  $\Delta pslBCD$  strains. Means  $\pm$  s.d. from triplicate experiments are shown;  $p < 0.05$ , one-way ANOVA.

biofilm formation via Psl production (figure 5e). Resistance of PAO1/*p<sub>BAD</sub>-psl* to ROS improved with increasing L-arabinose concentrations (figure 5f), indicating that Psl production is positively correlated with ROS resistance. Treatment with cellulase, which degrades Psl [58], rendered the PAO1/*p<sub>BAD</sub>-psl* sensitive to ROS treatment (figure 5g). Hence, Psl plays a major role in *P. aeruginosa* ROS resistance. Moreover, Psl acts as a signal for biofilm formation [43], thus could possibly provide positive feedback for biofilm formation and the emergence of RSCVs upon ROS exposure.

### 3.6. C-di-GMP signalling confers resistance to macrophage phagocytosis

ROS are mostly produced by host leucocytes, such as PMNs and macrophages, to kill the invading pathogens, which in turn induce c-di-GMP content to confer ROS resistance. Because the evolved RSCVs and the  $\Delta wspF$  mutant showed increased resistance to H<sub>2</sub>O<sub>2</sub> *in vitro*, we examined whether c-di-GMP signalling could protect *P. aeruginosa* from phagocytosis by RAW264.7 macrophages. Here, the  $\Delta wspF$  mutant and evolved RSCVs were more efficient in evading phagocytosis by macrophages than PAO1 (figure 6a,b). Although the PAO1/*p<sub>lac</sub>-yhjH* strain was subjected to lower phagocytosis levels by the macrophages than  $\Delta wspF$  mutant (figure 6b), we found that it was highly cytotoxic to macrophages compared with PAO1 and the  $\Delta wspF$  mutant (figure 6c). Hence, the lower macrophage phagocytosis level could be attributed to increased macrophage killing by PAO1/*p<sub>lac</sub>-yhjH*. Moreover, the PAO1/*p<sub>lac</sub>-yhjH* was exposed to higher ROS production from macrophages than PAO1 and the  $\Delta wspF$  mutant (figure 6d).


Further, Psl played a role in evading phagocytosis by macrophages, as  $\Delta pslBCD$ /*p<sub>lac</sub>-yedQ* was internalized at a higher

rate than PAO1/*p<sub>lac</sub>-yedQ* and  $\Delta pelA$ /*p<sub>lac</sub>-yedQ* (figure 6e). However, Psl was not involved in the cytotoxicity against macrophages, as Psl was not a virulence factor and there were no significant differences between PAO1/*p<sub>lac</sub>-yedQ* and  $\Delta pslBCD$ /*p<sub>lac</sub>-yedQ* in killing the macrophage cells (figure 6f). Nonetheless, increases in c-di-GMP levels by *p<sub>lac</sub>-yedQ* plasmid insertion reduced the cytotoxicity to macrophages, which corroborated the  $\Delta wspF$  mutant results (figure 6f).

## 4. Discussion

Resistance to oxidative stress is essential for pathogens to survive in the host environment. Here, we employed the adaptive experimental evolution assay to investigate *P. aeruginosa*'s ROS resistance via the emergence of RSCVs with enhanced biofilm forming capacity (figure 7). The production of superoxide in the phagosome was estimated at 1–4 M [59,60], implying that the use of a millimolar range of H<sub>2</sub>O<sub>2</sub> to induce pathogen evolution in our study was relevant to the host environment. We observed an adaptive evolution trait of mutagenesis in the *wspF* gene, resulting in c-di-GMP signal induction. Our findings are clinically significant as RSCVs with *wspF* mutations are frequently isolated from CF patients and these showed similar resistance to oxidative stress as our evolved RSCVs.

The regulatory role of c-di-GMP signalling on oxidative stress response is extendable to other pathogenic species, including *Burkholderia cenocepacia* and *Klebsiella pneumoniae* (electronic supplementary material, figure S3). The ROS-induced evolution of RSCVs could potentially explain the emergence of RSCVs by *B. cenocepacia* and *K. pneumoniae* during infections [61,62]. The induction of c-di-GMP signalling has been linked to increased production of Psl



**Figure 7.** Model of *Pseudomonas aeruginosa* adaptation to oxidative stress. Upon repeated exposure of oxidative stress, the cells evolved to form RSCVs via *wspF* mutation, resulting in the induction of *c*-di-GMP signalling and increased Psl production. This endowed RSCVs with the ability to resist oxidative stress and phagocytes.

exopolysaccharide in *P. aeruginosa* [50]. While Psl stiffens the biofilm structure, act as signal for biofilm formation and offers protection against antibiotics [43,63], the role of Psl as a barrier in the biofilm possibly reduces ROS penetration across bacterial membranes and causes cell damage. This confers bacterial cells with a biofilm-based protective mechanism from host immune cell generated ROS and/or antimicrobials.

As the oxidative stress resistance mechanism is commonly utilized by various pathogens, we propose the following strategies to modulate *c*-di-GMP signalling and treat biofilm-associated infections: (i) employing matrix-degrading enzymes, such as cellulase or the PslG hydrolase [64] to degrade Psl-like polysaccharides followed by effective killing of biofilm cells by antibiotics; and (ii) administering antioxidant drugs during early infection stages to prevent pathogen adaptation. To nullify *P. aeruginosa*'s oxidative stress adaptation in our evolution assays, we used the antioxidant L-glutathione, which reduced the emergence of RSCVs. This also indirectly reduced the resistance of *P. aeruginosa* to host immune clearance strategies such as phagocytosis. Given the lower levels of glutathione and increased oxidative stress from neutrophils in CF patients' lungs, antioxidant therapy could potentially prove effective against inflammation [65,66].

In summary, the interactions between the immune system and pathogens are highly complex, driving the pathogen to adapt accordingly to different host immune system stimuli.

*Pseudomonas aeruginosa* appears to draw a complex yet fine balance between its numerous DGCs and PDEs, thus leading to phenotypic variation, and ensuring the survival of its species. Hence, chemical manipulation of the *c*-di-GMP signalling pathway represents a promising strategy to manage chronic bacterial infections.

**Data accessibility.** The Whole Genome Shotgun bioproject for *P. aeruginosa* adaptation to ROS has been deposited at in the NCBI Short Read Archive (SRA) database with accession code SRP062804.

**Authors' contributions.** S.L.C., S.K., M.G. and L.Y. designed the research. S.L.C., Y.D. and J.Z. performed the experiments. Z.C. and S.S. performed and analysed LC-MS experiments. Y.L., D.I.D.-M. and S.C.S. performed and analysed DNA sequencing experiments. S.K. and M.G. analysed the data. S.L.C. and L.Y. wrote the paper. All authors read and approved the final manuscript.

**Competing interests.** The authors declare no competing financial interests.

**Funding.** This research was supported by the National Research Foundation and the Ministry of Education of Singapore under its Research Centre of Excellence Program. Y.L. is supported by the Start-up Grant (M4330002.C70) from Nanyang Technological University and AcRF Tier 2 (MOE2014-T2-2-172) from Ministry of Education, Singapore. S.L.C. is supported by the Lee Kong Chian Medicine Postdoctoral Fellowship 2015.

**Acknowledgements.** We thank Dr Gurjeet Singh Kohli for critical comments on our manuscript and fruitful discussions.

## References

- Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N. 2009 *Pseudomonas aeruginosa* biofilms in the respiratory tract of cystic fibrosis patients. *Pediatr. Pulmonol.* **44**, 547–558. (doi:10.1002/ppul.21011)
- Young D, Hussell T, Dougan G. 2002 Chronic bacterial infections: living with unwanted guests. *Nat. Immunol.* **3**, 1026–1032. (doi:10.1038/ni1102-1026)
- Domenech M, Ramos-Sevillano E, Garcia E, Moscoso M, Yuste J. 2013 Biofilm formation avoids complement immunity and phagocytosis of *Streptococcus pneumoniae*. *Infect. Immun.* **81**, 2606–2615. (doi:10.1128/IAI.00491-13)
- Alhede M, Bjarnsholt T, Givskov M, Alhede M. 2014 *Pseudomonas aeruginosa* biofilms: mechanisms of immune evasion. *Adv. Appl. Microbiol.* **86**, 1–40. (doi:10.1016/B978-0-12-800262-9.00001-9)
- Chiang WC, Nilsson M, Jensen PO, Hoiby N, Nielsen TE, Givskov M, Tolker-Nielsen T. 2013 Extracellular DNA shields against aminoglycosides in *Pseudomonas aeruginosa* biofilms. *Antimicrob. Agents Chemother.* **57**, 2352–2361. (doi:10.1128/AAC.00001-13)
- Hengge R. 2009 Principles of *c*-di-GMP signalling in bacteria. *Nat. Rev. Microbiol.* **7**, 263–273. (doi:10.1038/nrmicro2109)
- Romling U, Galperin MY, Gomelsky M. 2013 Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. *Microbiol. Mol. Biol. Rev.* **77**, 1–52. (doi:10.1128/MMBR.00043-12)
- Hickman JW, Tifrea DF, Harwood CS. 2005 A chemosensory system that regulates biofilm

- formation through modulation of cyclic diguanylate levels. *Proc. Natl Acad. Sci. USA* **102**, 14 422–14 427. (doi:10.1073/pnas.0507170102)
9. Paul R, Weiser S, Amiot NC, Chan C, Schirmer T, Giese B, Jenal U. 2004 Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. *Genes Dev.* **18**, 715–727. (doi:10.1101/gad.289504)
  10. Schmidt AJ, Ryjenkov DA, Gomelsky M. 2005 The ubiquitous protein domain EAL is a cyclic diguanylate-specific phosphodiesterase: enzymatically active and inactive EAL domains. *J. Bacteriol.* **187**, 4774–4781. (doi:10.1128/JB.187.14.4774-4781.2005)
  11. Christen M, Christen B, Folcher M, Schauerte A, Jenal U. 2005 Identification and characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control by GTP. *J. Biol. Chem.* **280**, 30 829–30 837. (doi:10.1074/jbc.M504429200)
  12. Chua SL *et al.* 2014 Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles. *Nat. Commun.* **5**, 4462. (doi:10.1038/ncomms5462)
  13. Chua SL, Hultqvist LD, Yuan M, Rybtke M, Nielsen TE, Givskov M, Tolker-Nielsen T, Yang L. 2015 In vitro and in vivo generation and characterization of *Pseudomonas aeruginosa* biofilm-dispersed cells via c-di-GMP manipulation. *Nat. Protoc.* **10**, 1165–1180. (doi:10.1038/nprot.2015.067)
  14. Lee VT, Matewish JM, Kessler JL, Hyodo M, Hayakawa Y, Lory S. 2007 A cyclic-di-GMP receptor required for bacterial exopolysaccharide production. *Mol. Microbiol.* **65**, 1474–1484. (doi:10.1111/j.1365-2958.2007.05879.x)
  15. Lim B, Beyhan S, Yildiz FH. 2007 Regulation of *Vibrio* polysaccharide synthesis and virulence factor production by CdgC, a GGDEF-EAL domain protein, in *Vibrio cholerae*. *J. Bacteriol.* **189**, 717–729. (doi:10.1128/JB.00834-06)
  16. Kuchma SL, Delalez NJ, Filkins LM, Snavely EA, Armitage JP, O'Toole GA. 2015 Cyclic di-GMP-mediated repression of swarming motility by *Pseudomonas aeruginosa* PA14 requires the MotAB stator. *J. Bacteriol.* **197**, 420–430. (doi:10.1128/JB.02130-14)
  17. Chua SL *et al.* 2015 C-di-GMP regulates *Pseudomonas aeruginosa* stress response to tellurite during both planktonic and biofilm modes of growth. *Sci. Rep.* **5**, 10052. (doi:10.1038/srep10052)
  18. Wong A, Rodrigue N, Kassen R. 2012 Genomics of adaptation during experimental evolution of the opportunistic pathogen *Pseudomonas aeruginosa*. *PLoS Genet.* **8**, e1002928. (doi:10.1371/journal.pgen.1002928)
  19. Pedersen SS, Koch C, Hoiby N, Rosendal K. 1986 An epidemic spread of multiresistant *Pseudomonas aeruginosa* in a cystic fibrosis centre. *J. Antimicrob. Chemother.* **17**, 505–516. (doi:10.1093/jac/17.4.505)
  20. Valerius NH, Koch C, Hoiby N. 1991 Prevention of chronic *Pseudomonas aeruginosa* colonisation in cystic fibrosis by early treatment. *Lancet* **338**, 725–726. (doi:10.1016/0140-6736(91)91446-2)
  21. Hartl D *et al.* 2007 Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nat. Med.* **13**, 1423–1430. (doi:10.1038/nm1690)
  22. Jensen PO *et al.* 2007 Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by *Pseudomonas aeruginosa*. *Microbiology* **153**, 1329–1338. (doi:10.1099/mic.0.2006/003863-0)
  23. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, Regelman W; Scientific advisory group, investigators, and coordinators of the epidemiologic study of cystic fibrosis. 2012 Multiple antibiotic-resistant *Pseudomonas aeruginosa* and lung function decline in patients with cystic fibrosis. *J. Cyst. Fibros.* **11**, 293–299. (doi:10.1016/j.jcf.2012.02.005)
  24. Pernet E *et al.* 2014 *Pseudomonas aeruginosa* eradicates *Staphylococcus aureus* by manipulating the host immunity. *Nat. Commun.* **5**, 5105. (doi:10.1038/ncomms6105)
  25. Marvig RL, Sommer LM, Molin S, Johansen HK. 2015 Convergent evolution and adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nat. Genet.* **47**, 57–64. (doi:10.1038/ng.3148)
  26. Huse HK, Kwon T, Zlosnik JE, Speert DP, Marcotte EM, Whiteley M. 2010 Parallel evolution in *Pseudomonas aeruginosa* over 39,000 generations in vivo. *MBio* **1**, e00199-10. (doi:10.1128/mBio.00199-10)
  27. Starkey M *et al.* 2009 *Pseudomonas aeruginosa* rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. *J. Bacteriol.* **191**, 3492–3503. (doi:10.1128/JB.00119-09)
  28. Boucher JC, Yu H, Mudd MH, Deretic V. 1997 Mucoid *Pseudomonas aeruginosa* in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. *Infect. Immun.* **65**, 3838–3846.
  29. Blanka A, Duvel J, Dotsch A, Klinkert B, Abraham WR, Kaever V, Ritter C, Narberhaus F, Haussler S. 2015 Constitutive production of c-di-GMP is associated with mutations in a variant of *Pseudomonas aeruginosa* with altered membrane composition. *Sci. Signal.* **8**, ra36. (doi:10.1126/scisignal.2005943)
  30. Almlad H, Harrison JJ, Rybtke M, Groizeleau J, Givskov M, Parsek MR, Tolker-Nielsen T. 2015 The cyclic AMP-Vfr signaling pathway in *Pseudomonas aeruginosa* is inhibited by cyclic di-GMP. *J. Bacteriol.* **197**, 2190–2200. (doi:10.1128/JB.00193-15)
  31. Williams HD, Zlosnik JE, Ryall B. 2007 Oxygen, cyanide and energy generation in the cystic fibrosis pathogen *Pseudomonas aeruginosa*. *Adv. Microb. Physiol.* **52**, 1–71. (doi:10.1016/S0065-2911(06)52001-6)
  32. Palmer KL, Aye LM, Whiteley M. 2007 Nutritional cues control *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum. *J. Bacteriol.* **189**, 8079–8087. (doi:10.1128/JB.01138-07)
  33. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Hoiby N, Molin S. 2008 In situ growth rates and biofilm development of *Pseudomonas aeruginosa* populations in chronic lung infections. *J. Bacteriol.* **190**, 2767–2776. (doi:10.1128/JB.01581-07)
  34. Moriarty TF, McElroy JC, Elborn JS, Tunney MM. 2007 Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. *Pediatr. Pulmonol.* **42**, 1008–1017. (doi:10.1002/ppul.20671)
  35. Reid DW, Misso N, Aggarwal S, Thompson PJ, Walters EH. 2007 Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. *Respirology* **12**, 63–69. (doi:10.1111/j.1440-1843.2006.00962.x)
  36. Barrett RD, MacLean RC, Bell G. 2005 Experimental evolution of *Pseudomonas fluorescens* in simple and complex environments. *Am. Nat.* **166**, 470–480. (doi:10.1086/444440)
  37. Irie Y, Starkey M, Edwards AN, Wozniak DJ, Romeo T, Parsek MR. 2010 *Pseudomonas aeruginosa* biofilm matrix polysaccharide Psl is regulated transcriptionally by RpoS and post-transcriptionally by RsmA. *Mol. Microbiol.* **78**, 158–172. (doi:10.1111/j.1365-2958.2010.07320.x)
  38. Chua SL *et al.* 2016 Selective labelling and eradication of antibiotic-tolerant bacterial populations in *Pseudomonas aeruginosa* biofilms. *Nat. Commun.* **7**, 10750. (doi:10.1038/ncomms10750)
  39. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Hoiby N. 2009 Antibiotic resistance in *Pseudomonas aeruginosa* strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. *Antimicrob. Agents Chemother.* **53**, 2483–2491. (doi:10.1128/AAC.00428-08)
  40. Mouneimne H, Robert J, Jarlier V, Cambau E. 1999 Type II topoisomerase mutations in ciprofloxacin-resistant strains of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **43**, 62–66.
  41. Tran CS, Rangel SM, Almlad H, Kierbel A, Givskov M, Tolker-Nielsen T, Hauser AR, Engel JN. 2014 The *Pseudomonas aeruginosa* type III translocon is required for biofilm formation at the epithelial barrier. *PLoS Pathog.* **10**, e1004479. (doi:10.1371/journal.ppat.1004479)
  42. Irie Y, Borlee BR, O'Connor JR, Hill PJ, Harwood CS, Wozniak DJ, Parsek MR. 2012 Self-produced exopolysaccharide is a signal that stimulates biofilm formation in *Pseudomonas aeruginosa*. *Proc. Natl Acad. Sci. USA* **109**, 20 632–20 636. (doi:10.1073/pnas.1217993109)
  43. Kolpen M *et al.* 2010 Polymorphonuclear leucocytes consume oxygen in sputum from chronic *Pseudomonas aeruginosa* pneumonia in cystic fibrosis. *Thorax* **65**, 57–62. (doi:10.1136/thx.2009.114512)
  44. Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ. 2006 Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. *J. Biol. Chem.* **281**, 39 860–39 869. (doi:10.1074/jbc.M605898200)
  45. Yang L *et al.* 2011 Evolutionary dynamics of bacteria in a human host environment. *Proc. Natl Acad. Sci. USA* **108**, 7481–7486. (doi:10.1073/pnas.1018249108)

46. Oberhardt MA, Goldberg JB, Hogardt M, Papin JA. 2010 Metabolic network analysis of *Pseudomonas aeruginosa* during chronic cystic fibrosis lung infection. *J. Bacteriol.* **192**, 5534–5548. (doi:10.1128/JB.00900-10)
47. Suttorp N, Toepfer W, Roka L. 1986 Antioxidant defense mechanisms of endothelial cells: glutathione redox cycle versus catalase. *Am. J. Physiol.* **251**, C671–C680.
48. Borlee BR, Goldman AD, Murakami K, Samudrala R, Wozniak DJ, Parsek MR. 2010 *Pseudomonas aeruginosa* uses a cyclic-di-GMP-regulated adhesion to reinforce the biofilm extracellular matrix. *Mol. Microbiol.* **75**, 827–842. (doi:10.1111/j.1365-2958.2009.06991.x)
49. Rybtke MT, Borlee BR, Murakami K, Irie Y, Hentzer M, Nielsen TE, Givskov M, Parsek MR, Tolker-Nielsen T. 2012 Fluorescence-based reporter for gauging cyclic di-GMP levels in *Pseudomonas aeruginosa*. *Appl. Environ. Microbiol.* **78**, 5060–5069. (doi:10.1128/AEM.00414-12)
50. Chen Y *et al.* 2015 Multiple diguanylate cyclase-coordinated regulation of pyoverdine synthesis in *Pseudomonas aeruginosa*. *Environ. Microbiol. Rep.* **7**, 498–507. (doi:10.1111/1758-2229.12278)
51. Frangipani E, Visaggio D, Heeb S, Kaever V, Camara M, Visca P, Imperi F. 2014 The Gac/Rsm and cyclic-di-GMP signalling networks coordinately regulate iron uptake in *Pseudomonas aeruginosa*. *Environ. Microbiol.* **16**, 676–688. (doi:10.1111/1462-2920.12164)
52. Chua SL, Tan SY, Rybtke MT, Chen Y, Rice SA, Kjelleberg S, Tolker-Nielsen T, Yang L, Givskov M. 2013 Bis-(3'-5')-cyclic dimeric GMP regulates antimicrobial peptide resistance in *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* **57**, 2066–2075. (doi:10.1128/AAC.02499-12)
53. Smania AM, Segura I, Pezza RJ, Becerra C, Albesa I, Argarana CE. 2004 Emergence of phenotypic variants upon mismatch repair disruption in *Pseudomonas aeruginosa*. *Microbiology* **150**, 1327–1338. (doi:10.1099/mic.0.26751-0)
54. D'Argenio DA, Calfee MW, Rainey PB, Pesci EC. 2002 Autolysis and autoaggregation in *Pseudomonas aeruginosa* colony morphology mutants. *J. Bacteriol.* **184**, 6481–6489. (doi:10.1128/JB.184.23.6481-6489.2002)
55. Sanchez-Torres V, Hu H, Wood TK. 2011 GGDEF proteins Yeal, YedQ, and YfiN reduce early biofilm formation and swimming motility in *Escherichia coli*. *Appl. Microbiol. Biotechnol.* **90**, 651–658. (doi:10.1007/s00253-010-3074-5)
56. Hengge R, Galperin MY, Ghigo JM, Gomelsky M, Green J, Hughes KT, Jenal U, Landini P. 2016 Systematic nomenclature for GGDEF and EAL domain-containing cyclic Di-GMP turnover proteins of *Escherichia coli*. *J. Bacteriol.* **198**, 7–11. (doi:10.1128/JB.00424-15)
57. Pesavento C, Becker G, Sommerfeldt N, Possling A, Tschowri N, Mehli A, Hengge R. 2008 Inverse regulatory coordination of motility and curli-mediated adhesion in *Escherichia coli*. *Genes Dev.* **22**, 2434–2446. (doi:10.1101/gad.475808)
58. Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ. 2009 Assembly and development of the *Pseudomonas aeruginosa* biofilm matrix. *PLoS Pathog.* **5**, e1000354. (doi:10.1371/journal.ppat.1000354)
59. Dupre-Crochet S, Erard M, Nubetae O. 2013 ROS production in phagocytes: why, when, and where? *J. Leukoc. Biol.* **94**, 657–670. (doi:10.1189/jlb.1012544)
60. Segal AW. 2005 How neutrophils kill microbes. *Annu. Rev. Immunol.* **23**, 197–223. (doi:10.1146/annurev.immunol.23.021704.115653)
61. Bernier SP, Nguyen DT, Sokol PA. 2008 A LysR-type transcriptional regulator in *Burkholderia cenocepacia* influences colony morphology and virulence. *Infect. Immun.* **76**, 38–47. (doi:10.1128/IAI.00874-07)
62. Takahashi M, Yoshida K, San Clemente CL. 1977 Relation of colonial morphologies in soft agar to morphological and biological properties of the K-9 strain of *Klebsiella pneumoniae* and its variants. *Can. J. Microbiol.* **23**, 448–451. (doi:10.1139/m77-066)
63. Billings N, Millan M, Caldara M, Rusconi R, Tarasova Y, Stocker R, Ribbeck K. 2013 The extracellular matrix component Psl provides fast-acting antibiotic defense in *Pseudomonas aeruginosa* biofilms. *PLoS Pathog.* **9**, e1003526. (doi:10.1371/journal.ppat.1003526)
64. Yu S *et al.* 2015 PslG, a self-produced glycosyl hydrolase, triggers biofilm disassembly by disrupting exopolysaccharide matrix. *Cell Res.* **25**, 1352–1367. (doi:10.1038/cr.2015.129)
65. Galli F *et al.* 2012 Oxidative stress and antioxidant therapy in cystic fibrosis. *Biochim. Biophys. Acta* **1822**, 690–713. (doi:10.1016/j.bbdis.2011.12.012)
66. Ciofu O, Lykkesfeldt J. 2014 Antioxidant supplementation for lung disease in cystic fibrosis. *Cochrane Database Syst. Rev.* **8**, CD007020. (doi:10.1002/14651858.CD007020.pub3)